Argen X SE - ADR

Argen X SE - ADR

ARGX

Market Cap$38.85B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Argen X SE - ADRArgen X SE - ADR-376.7--2%17.3-

Earnings Call Q3 2024

October 31, 2024 - AI Summary

**Strong Financial Performance**: Argenx reported a total operating income of $589 million for Q3 2024, with product net sales reaching $573 million, reflecting a 20% quarter-over-quarter growth and a 74% increase compared to the prior year. This suggests robust demand for their leading product, VYVGART, primarily in the gMG (generalized Myasthenia Gravis) indication.
**CIDP Launch Metrics**: The CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) launch showed promising progress, with over 300 patients treated by the end of the quarter. Approximately 85-90% of these patients are switching from IVIg, aligning with expectations. However, the growth in patient starts has been linear, which means that the launch growth appears to be steady but not explosive.
**Market Dynamics and Payer Relationships**: Argenx has successfully secured coverage for around 54% of U.S. commercial lives for CIDP. Most payer policies require prior exposure to immunoglobulin therapy, which is typical for this type of treatment. Ongoing negotiations and policy adjustments will be crucial for continued growth; however, these requirements may pose a barrier to rapid market penetration.

Exclusive for Stockcircle Pro members

Sign upSign Up
$705.50

Target Price by Analysts

10.4% upsideArgen X SE Target Price DetailsTarget Price
$413.16

Current Fair Value

35.3% downside

Overvalued by 35.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$38.85 Billion
Enterprise Value$37.43 Billion
Dividend Yield$0 (0%)
Earnings per Share$-5.16
Beta0.24
Outstanding Shares60,087,498

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-376.73
PEG166.81
Price to Sales17.27
Price to Book Ratio9.13
Enterprise Value to Revenue16.57
Enterprise Value to EBIT-97
Enterprise Value to Net Income-368
Total Debt to Enterprise0
Debt to Equity0

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Argen X SE

CEO: Tim Van Hauwermeiren